Sotax automated HPLC-dissolution platform

Forecast overview

Subagency

FDA

NAICS

334516

Program office

CDER ACQUISITION

The purrchase of this instrument enhances OPQ lab testing capability for generic drugs. Replacement of the current Waters Alliance dissolution platform as well as the USP 2 apparatus, which is over 15 years old and no longer supported by the vendor with increasingly difficult parts procurement. This equipment is essential for OPQR laboratory operations to conduct dissolution studies that directly support OPQ mission objectives and research goals, ensuring continued analytical capability for drug product testing. The work performed with this instrument will support GDUFA program needs.

Source

Source

HHS SBCX Forecast Export

Source file

Forecast.csv

Official source

Agency forecast source

Last verified

2026-08-31

Agency-published contact: · TBD@fda.hhs.gov

Forecast research and capture tools

Compare this forecast with broader federal opportunity volume and mix.

• 2026 Federal Opportunity Benchmark
• Federal Opportunity Research hub
• Best capture management software guide
• Free opportunity alerts for upcoming notices